Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics PLC (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
$13.85
$0.42(2.31%)
At close: 4:00 PM EST
$13.85
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$13.83 - $36.91
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.67M
Market Cap
$10.73B
Enterprise Value$10.08B
Total Cash (Recent Filing)$238.88M
Total Debt (Recent Filing)$5.43M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Mar 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding744,442,570
10 Day Avg. Volume3,156,406
30 Day Avg. Volume2,672,767
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)32.99
Price to Sales (P/S)0.00
P/FCF Ratio-90.17
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-669.84
Enterprise Value/Ebitda-10.94
Forecast
1Y Price Target
$49.48Price Target Upside257.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyClinical data indicate ivonescimab outperforms Keytruda for certain first‑line lung cancer patients and shows activity in EGFR‑mutant cases, supporting a differentiated clinical profile that could drive uptake.
Pipeline AdvancementAdvancing Phase III programs and initiation plans for the HARMONi‑GI3 study demonstrate progress in the development pipeline and set the stage for upcoming clinical readouts.
Strategic PartnershipCollaboration with GlaxoSmithKline to test ivonescimab with a B7‑H3 antibody‑drug conjugate expands combination opportunities and leverages partner operational capabilities while maintaining shared rights.
Bears Say
Financing And Dilution RiskPotential need for additional capital to fund late‑stage development raises the risk of shareholder dilution, which could pressure the stock if financing becomes necessary.
Regulatory Approval UncertaintyFDA approval risk remains because regulators in this treatment setting typically prioritize statistically significant overall survival, creating a high bar for approval.
Trial Design And Regional ComplexityThe global design of HARMONi, with substantial participation from China, increases complexity that could complicate interpretation of survival results and draw added regulatory scrutiny.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics PLC’s price range in the past 12 months?
Summit Therapeutics PLC lowest stock price was $13.83 and its highest was $36.91 in the past 12 months.
What is Summit Therapeutics PLC’s market cap?
Summit Therapeutics PLC’s market cap is $10.73B.
When is Summit Therapeutics PLC’s upcoming earnings report date?
Summit Therapeutics PLC’s upcoming earnings report date is Mar 12, 2026 which is in 34 days.
How were Summit Therapeutics PLC’s earnings last quarter?
Summit Therapeutics PLC released its earnings results on Oct 20, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.14.
Is Summit Therapeutics PLC overvalued?
According to Wall Street analysts Summit Therapeutics PLC’s price is currently Undervalued.
Does Summit Therapeutics PLC pay dividends?
Summit Therapeutics PLC does not currently pay dividends.
What is Summit Therapeutics PLC’s EPS estimate?
Summit Therapeutics PLC’s EPS estimate is -0.09.
How many shares outstanding does Summit Therapeutics PLC have?
Summit Therapeutics PLC has 744,442,570 shares outstanding.
What happened to Summit Therapeutics PLC’s price movement after its last earnings report?
Summit Therapeutics PLC reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -4.526%.
Which hedge fund is a major shareholder of Summit Therapeutics PLC?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.48 (257.26% Upside)
$49.48 (257.26% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.34%
12-Months-Change
Fundamentals
Return on Equity
-292.49%
Trailing 12-Months
Asset Growth
-47.95%
Trailing 12-Months
Company Description
Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results and expansion plans with multiple Phase III trials, indicating significant progress and potential for ivonescimab in various cancer treatments. However, financial concerns and increased expenses were noted as challenges.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$49.48
▲(257.26% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---